Allakos is a clinical stage biotechnology company. The company is developing AK002, its wholly owned monoclonal antibody, for the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic esophagitis and mast cell related diseases. AK002 selectively targets both eosinophils and mast cells, white blood cells that are distributed in the body and play a primary role in the inflammatory response. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a number of severe diseases.

Atrion develops and manufactures products, primarily for medical applications. The company's fluid delivery products include valves designed to fill, hold and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter and other applications. The company's primary cardiovascular products is the MPS2? Myocardial Protection System, which is used in open-heart surgery that delivers to the heart essential fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The company also manufactures medical devices that disinfect contact lenses and balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.

Becton, Dickinson and Company is a medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The company's segments are: BD Medical, which produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings; BD Life Sciences, which provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers; and BD Interventional, which provides vascular, urology, oncology and surgical products.

Eagle Pharmaceuticals is a pharmaceutical company focused on developing and commercializing injectable products, mainly in the critical care and oncology areas, using the U.S. Food and Drug Administration's (FDA's) 505(b)(2) New Drug Application regulatory pathway. The company's product portfolio includes four products: Argatroban, an anti-coagulant, thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex, a muscle relaxant for malignant hyperthermia; Belrapzo; and Bendeka. The company also has advanced product candidates which include EP-4104 (dantrolene sodium for exertional heat stroke), EP-5101 (PEMFEXY?), a pemetrexed injection ready-to-dilute formulation and EGL-5385-C-1701 (fulvestrant).

Entergy is a holding company. Through its subsidiaries, the company is an integrated energy company engaged mainly in electric power production and retail distribution operations. The company owns and operates power plants. The company has two segments: Utility, which generates, transmits, distributes and sells electric power to retail and wholesale customers in Arkansas, Louisiana, Mississippi, and Texas; and Entergy Wholesale Commodities, which includes the ownership, operation, and decommissioning of nuclear power plants, located in the northern United States, the sale of the electric power produced by its operating plants to wholesale customers, and also provides services to other nuclear power plant owners.

Kimberly-Clark is principally engaged in the manufacturing and marketing of a range of products primarily made from natural or synthetic fibers using technologies in fibers, nonwovens and absorbency. The company is organized into three operating segments: Personal Care, which provides solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products; Consumer Tissue, which provides facial and bathroom tissue, paper towels, napkins and related products; and K-C Professional, which provides a range of solutions and supporting products such as wipers, tissue, towels, apparel, soaps and sanitizers.

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company employs research technologies such as antibody discovery technologies, structure-based drug design, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. The company's collaboration partners and licensees have programs in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

LiveRamp Holdings is a global technology company. The company provides enterprise customer management platform that help organizations utilize customer data to deliver products and experiences. A main component of the company's platform is the omnichannel, deterministic identity graph. Utilizing the company's identity graph, the LiveRamp platform resolves a customer's data (first-, second-, or third-party) to consumer identifiers that represent real people in a way that protects consumer privacy.

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The company's product categories are: biologics, which include Crysvita? (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii? (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia.